TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Recruiting
AstraZeneca
Phase 2
2016-03-14
The purpose of the study is to learn from the real world practice of prescribing targeted
therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be
a drug target or to predict sensitivity to a drug.
NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant
biomarkers. For additional information, contact TAPUR@asco.org, or if a patient, your nearest
participating TAPUR site (see participating centers).
*********************************************************************************************
*********************************************************************************
Results in publication or poster presentation format are posted as they become available for
individual cohorts at www.tapur.org/news. The results may be accessed at any time. All
results will be made available on clinicaltrials.gov at the end of the study. Indexing of
available results on PubMed is in progress.
*********************************************************************************************
*********************************************************************************
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Recruiting
Bayer
Phase 2
2016-03-14
The purpose of the study is to learn from the real world practice of prescribing targeted
therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be
a drug target or to predict sensitivity to a drug.
NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant
biomarkers. For additional information, contact TAPUR@asco.org, or if a patient, your nearest
participating TAPUR site (see participating centers).
*********************************************************************************************
*********************************************************************************
Results in publication or poster presentation format are posted as they become available for
individual cohorts at www.tapur.org/news. The results may be accessed at any time. All
results will be made available on clinicaltrials.gov at the end of the study. Indexing of
available results on PubMed is in progress.
*********************************************************************************************
*********************************************************************************
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Recruiting
Boehringer Ingelheim
Phase 2
2016-03-14
The purpose of the study is to learn from the real world practice of prescribing targeted
therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be
a drug target or to predict sensitivity to a drug.
NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant
biomarkers. For additional information, contact TAPUR@asco.org, or if a patient, your nearest
participating TAPUR site (see participating centers).
*********************************************************************************************
*********************************************************************************
Results in publication or poster presentation format are posted as they become available for
individual cohorts at www.tapur.org/news. The results may be accessed at any time. All
results will be made available on clinicaltrials.gov at the end of the study. Indexing of
available results on PubMed is in progress.
*********************************************************************************************
*********************************************************************************
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.